Different Molecular Signatures in Magnetic Resonance Imaging-Staged Facioscapulohumeral Muscular Dystrophy Muscles by Tasca, Giorgio et al.
















1Don Carlo Gnocchi Onlus Foundation, Milan, Italy, 2Department of Bioinformatics, Erasmus MC, Rotterdam, The Netherlands, 3Crosslinks BV, Rotterdam, The
Netherlands, 4Porto Conte Ricerche Srl, Tramariglio, Alghero (SS), Italy, 5Institute of Neurology, Catholic University School of Medicine, Rome, Italy, 6Department of
Radiology, Istituto Dermopatico dell’Immacolata IRCCS, Rome, Italy
Abstract
Background: Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common muscular dystrophies and is
characterized by a non-conventional genetic mechanism activated by pathogenic D4Z4 repeat contractions. By muscle
Magnetic Resonance Imaging (MRI) we observed that T2-short tau inversion recovery (T2-STIR) sequences identify two
different conditions in which each muscle can be found before the irreversible dystrophic alteration, marked as T1-weighted
sequence hyperintensity, takes place. We studied these conditions in order to obtain further information on the molecular
mechanisms involved in the selective wasting of single muscles or muscle groups in this disease.
Methods: Histopathology, gene expression profiling and real time PCR were performed on biopsies from FSHD muscles
with different MRI pattern (T1-weighted normal/T2-STIR normal and T1-weighted normal/T2-STIR hyperintense). Data were
compared with those from inflammatory myopathies, dysferlinopathies and normal controls. In order to validate obtained
results, two additional FSHD samples with different MRI pattern were analyzed.
Results: Myopathic and inflammatory changes characterized T2-STIR hyperintense FSHD muscles, at variance with T2-STIR
normal muscles. These two states could be easily distinguished from each other by their transcriptional profile. The
comparison between T2-STIR hyperintense FSHD muscles and inflammatory myopathy muscles showed peculiar changes,
although many alterations were shared among these conditions.
Conclusions: At the single muscle level, different stages of the disease correspond to the two MRI patterns. T2-STIR
hyperintense FSHD muscles are more similar to inflammatory myopathies than to T2-STIR normal FSHD muscles or other
muscular dystrophies, and share with them upregulation of genes involved in innate and adaptive immunity. Our data
suggest that selective inflammation, together with perturbation in biological processes such as neoangiogenesis, lipid
metabolism and adipokine production, may contribute to the sequential bursts of muscle degeneration that involve
individual muscles in an asynchronous manner in this disease.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is an inher-
ited myopathy often characterized by asymmetric muscle involve-
ment [1]. The clinical phenotype of FSHD patients can be
heterogeneous, ranging from asymptomatic to wheelchair bound
individuals, with wide intrafamilial variability [2]. Extramuscular
manifestations may include abnormalities in the retinal vasculature
[3].
FSHD is associated with a contraction in a macrosatellite repeat
array in the 4q35 chromosomal region D4Z4 [4]. Alterations in
the expression of several ‘‘candidate’’ genes, both in cis and in trans
to the pathogenic 4q35 allele, have been proposed to act as major
characters in carrying out muscle damage, but their disregulation
in FSHD is still a controversial finding [5,6]. Recent studies
significantly improved the understanding of FSHD genetics and
suggested a toxic role of a stabilized DUX4 transcript transcribed
from the contracted D4Z4 array [7,8]. However, despite large
progresses in the characterization of the genetic mechanism of the
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sequence of molecular events associating a potentially cytotoxic
lesion with the natural history of the disease are still incompletely
described and deserve further investigation.
In muscle disease, microarray gene expression analyses have
been widely used to characterize molecular aspects of muscle
pathology [9–12]. By the use of this technology, several alterations
have been described in FSHD muscle, linking the pathogenic
process to altered angiogenesis, susceptibility to oxidative stress
and abnormal muscle differentiation [13–15].
Muscle magnetic resonance imaging (MRI) has been lately
introduced into clinical and research practice as a non-invasive
and sensitive technique to evaluate the involvement of individual
muscles in different myopathies [16,17]. In FSHD [18,19],
together with muscles showing normal MRI signal and muscles
showing abnormalities on T1-weighted (T1-W) MRI sequences
(corresponding to areas of fatty fibrous replacement), different
authors [20–23] have documented the presence of areas charac-
terized by increased signal on T2- short tau inversion recovery
(T2-STIR) sequences also in muscles not yet replaced by fat tissue,
i.e. showing a normal signal on T1-W sequences. This type of
alteration is present in other muscle diseases and reflects an
increase in tissue water content usually thought to account for
muscle oedema [20] and to underlie an ongoing inflammatory
process.
To characterize the pathological changes associated with T2-
STIR hyperintensity in FSHD muscle tissue, we performed
histopathology and microarray analysis of a set of FSHD biopsies
and compared T1-W normal/T2-STIR hyperintense muscle (T2-
STIR +) with muscle showing absence of pathological signs on
both T1-W and T2-STIR images (T2-STIR -) (Figure S1).
Methods
Ethics statement
The Ethics Committee of the Catholic University School of
Medicine approved this study. Written informed consent was
obtained from all patients.
Patients and sample collection
Unrelated, genetically confirmed (D4Z4 EcoRI fragment
,40Kb) FSHD patients who had undergone lower limb muscle
MRI were considered as candidates for the study. MRI was
performed as described elsewhere [21]. Patients who met the
inclusion criteria (i.e. i- having at least one muscle showing
hyperintensity on T2-STIR sequences, or ii- having normal T1-W
and T2-STIR sequence signal on quadriceps muscle) were asked
to undergo needle muscle biopsy. Exceptions to this procedure are
constituted by sample 1, acquired from an open biopsy made for
diagnostic purposes and sample 2, collected during orthopedic
surgery. T2-STIR hyperintensity of the corresponding muscles
had been previously documented for these samples as well. Twelve
FSHD muscle biopsies were obtained from muscles with different
MRI signal (6 T2-STIR + and 6 T2-STIR 2). The samples were
collected according to standard procedures and whenever possible,
depending on the sample size, a fragment for histological analysis
(frozen in isopentane cooled in liquid nitrogen) and a fragment for
RNA extraction (immediately frozen in liquid nitrogen) were
taken. Most of the samples underwent both histopathological and
gene expression analysis (Table 1). Two of the samples, one T2-
STIR + and one T2-STIR – were taken from different muscles of
the same patient.
We also included in the study 7 normal controls (age range 18–
58), 7 immunopathologically characterized inflammatory myopa-
thies (IM) (2 dermatomyositis, DM, 2 polymyositis, PM, 1
necrotizing myopathy and 2 IM with nonspecific histopathological
features) (age range 23–73) and 4 dysferlinopathies (LGMD2B)
(age range 28–35). Non-FSHD samples were obtained for
diagnostic purposes.
To provide a biological validation of our findings, two
additional biopsies were performed in FSHD muscles showing
different MRI patterns (T2-STIR + validation and T2-STIR –
validation) and analyzed.
Muscle histology
Eleven FSHD samples (5 T2-STIR + and 6 T2-STIR 2) were
available for histological analysis, which included hematoxylin-
eosin and, whenever possible, routine diagnostic stainings (nico-
tinamide adenine dinucleotide dehydrogenase tetrazolium reduc-
tase, succinate dehydrogenase, cytochrome-C oxidase, modified
Gomori trichrome, alkaline phosphatase, and periodic acid-Schiff).
Immunohistochemistry protocol for inflammatory markers and
antibodies used are described elsewhere [21].
Gene expression and real time PCR
Eight FSHD samples (4 T2-STIR + and 4 T2-STIR 2) were
available for gene expression analysis. Total RNA was extracted
by TriZol (TriZol reagent, Invitrogen, Carlsbad, CA, USA) and
further purified using the RNAeasy mini kit following the RNA
cleanup protocol as indicated by the manufacturer (Qiagen,
Valencia, CA, USA). RNA purity and integrity were assessed by
spectrophotometric analysis and agarose gel electrophoresis. We
made use of the Illumina BeadChips technology to analyze the
expression of .31,000 annotated genes with more than 47,000
probes using the HumanHT-12v4 Expression BeadChip (Illumina
Inc., San Diego, CA, USA). Gene expression data were extracted
and normalized using Illumina Genome Studio and analyzed
using BRB-ArrayTools, developed by R. Simon and BRB-
ArrayTools Development Team. To discriminate the gene
expression variations that characterize T2-STIR + FSHD muscles
with respect to T2-STIR – FSHD and IM muscles we computed
the probability of genes being differentially expressed between the
classes using the unequal variance t test as implemented in BRB-
ArrayTools. A per gene estimate of false discovery rate was
computed using the method of Benjamini and Hochberg [24] A
MIAME compliant description of the experiment and full dataset
have been submitted to the Gene Expression Omnibus public
database (www.ncbi.nlm.nih.gov/geo, (GSE26852)). Methods
used for gene set expression comparison and real time PCR are
detailed in Supporting Information (Text S1).
Power analysis
To define the minimum fold-change threshold we could
confidently interpret as a true change given the size of our study
sample, we made use of the SampleSize R package implemented
in BRB-ArrayTools (Sample size determination in microarray




Routine histopathology displayed moderate to marked myo-
pathic features in T2-STIR + FSHD muscles (Figure S2).
Inflammatory infiltrates with CD8+ cell predominance in the
endomysium and CD4+ cell predominance in the perimysium
were present in all the samples obtained from T2-STIR + FSHD
muscles (Figure S3). Further details about the immunocharacter-
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paper [21]. In some cases the alterations also included mild
increase in endomysial and perimysial connective tissue. Necrosis
and myophagias were evident in sample 2, 4 and 5. Some T2-
STIR + FSHD samples displayed the presence of adipocytes in
perimysial areas. By contrast, samples obtained from 6 T2-STIR –
FSHD muscles displayed only mild or minimal myopathic changes
and no inflammation was evident on them. Histopathology results
are summarized in Table 1.
Gene expression
Comparison of T2-STIR hyperintense FSHD muscles
transcriptional pattern with that of T2-STIR normal
muscles. To visualize the correlation relationships among our
FSHD samples we made use of multidimensional scaling (MDS)
analysis, by which samples are positioned in a 3D space on the
basis of first three principal components of variability. Based on
the expression level of all the 29045 probesets showing detection p-
value greater than 0.05, FSHD samples formed two separate
clusters corresponding to T2-STIR + and T2-STIR – muscles. A
similar clustering pattern of the samples could be observed by
Hierarchical clustering analysis (Figure 1A and 1B). FSHD
samples, including the two biopsies taken from the same patient,
were split into two subgroups according to their MRI pattern.
Transcripts differentially expressed between T2-STIR
hyperintense and T2-STIR normal FSHD muscles. To
describe at the molecular level the on-going process responsible
for the observed differences between MRI patterns of FSHD
muscle, we compared the expression profiles of T2-STIR + and
T2-STIR – FSHD muscles. We first assessed the power of
statistical analysis and estimated that our sample size of 4 samples
per class was sufficient to confidently identify differences larger
than 1log2, if taking into account the 75
th percentile of the
variance distribution.
Table 1. Summary table of FSHD samples.





biceps femoris 37 open marked myopathic changes, endomysial
and perimysial connective tissue +,






paravertebral 31 open marked myopathic changes, endomysial
and perimysial connective tissue ++,
adipocytes +, necrotic fibers with
invading macrophages ++, endomysial





quadriceps 37 needle moderate myopathic changes,




quadriceps 38 needle moderate myopathic changes, necrotic
and regenerating fibers +, endomysial





quadriceps 20 needle moderate/marked myopathic changes,
interstitial oedema and slightly enlarged






biceps femoris 50 needle not available yes
7 T1-W and T2-STIR
normal
quadriceps 25 needle mild myopathic changes, no
inflammation
yes
8 T1-W and T2-STIR
normal
quadriceps 33 needle mild myopathic changes, no
inflammation
not available
9 T1-W and T2-STIR
normal
quadriceps 51 needle mild myopathic changes, no
inflammation
yes
10 T1-W and T2-STIR
normal
quadriceps 36 needle minimal myopathic changes, no inflammation not available
11 T1-W and T2-STIR
normal
quadriceps 26 needle minimal myopathic changes, no
inflammation
yes
12* T1-W and T2-STIR
normal
quadriceps 31 needle mild myopathic changes, no
inflammation
yes
T2-STIR + validation T1-W normal/T2-STIR
hyperintense
quadriceps 36 needle not available yes
T2-STIR – validation T1-W and T2-STIR
normal
quadriceps 36 needle not available yes
+ = mild increase, ++ = moderate increase, +++ = marked increase. * samples from the same patient.
doi:10.1371/journal.pone.0038779.t001
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differentially expressed between the two classes with high statistical
significance (p,0.005, 805 with p,0.001). These 1948 probesets,
1089 of which were upregulated, correspond to 1752 different
transcripts. A table reporting all the significant probesets, ranked
by fold change and tabulated along with between-classes p-value,
within-class geometric mean, between-classes fold difference and
links to NCBI annotations, is posted under Supporting Informa-
tion (Table S1).
We also tested the hypothesis that individual gene sets were
statistically different between the classes by using the gene set class
comparison tool implemented in BRB-ArrayTools to query the
BioCarta, Gene Ontology, and KEGG databases (Table S2). As a
result of this analysis, also integrated by additional available public
information on gene function and pathways, a number of the
modulated genes have been assigned to the following functional
categories: i) Inflammation; ii) Extracellular matrix (ECM)
remodeling; iii) Muscle regeneration (Figure 2).
Comparison of FSHD muscles transcriptional pattern
with that of muscles from other myopathies and normal
controls. We used MDS to plot our T2-STIR+ and T2-STIR-
samples in a 3D gene expression space together with muscles from
normal individuals and patients affected by different types of
muscle diseases. As shown in Figure 1A, samples appeared grossly
distributed in two large clusters. Samples showing the highest
degree of similarity to T2-STIR + FSHD were inflammatory
myopathies (IM), and in particular polymyositis (PM). According-
ly, a larger dispersion of the average expression ratios could be
observed in a scatter plot analysis of T2-STIR+ vs T2-STIR-
FSHD samples respect to T2-STIR+ vs IM (Figure 1C).
Dysferlinopathy (DYSF) samples appeared broadly distributed,
and distant from T2-STIR + FSHD. We also started character-
izing the subtle differences between T2-STIR + FSHD and IM
muscles. We identified a group of 286 probesets differentially
expressed with a significance level of p,0.005 (Table S3). These
286 probe sets, 176 of which were upregulated, were represen-
tative of 229 different genes. The differences between T2-STIR +
FSHD muscles and IM mainly mapped to the functional
categories: i) Angiogenesis; ii) Adipocyte presence, glycerolipid
metabolism and adipokine production (Table 2). Two tables
reporting all the significant genes (table S3) and pathways
Figure 1. Class discovery graphical displays and scatter plot. (A) Unsupervised hierarchical clustering showing correlation relationships
among samples. T2-STIR + FSHD samples are evidently separated from T2-STIR – FSHDs and group with IM (framed in red). T2-STIR – FSHDs show
higher correlation with normal controls and one of the dysferlinopathies (framed in green). (B) Multidimensional scaling. Each sample is represented
by a sphere in a 3D space. Samples with similar expression profile are shown close together. Note the peculiar and distinct spatial collocation of T2-
STIR + FSHD samples clustering together with IM. (C) Scatter plot representation of average transcript expression levels in T2-STIR + FSHD muscles
(n=4) compared to T2-STIR – FSHD muscles (n=4) or to inflammatory myopathies (n=7).
doi:10.1371/journal.pone.0038779.g001
Figure 2. Schematic representation of the molecular pathways modulated in T2-STIR + FSHD samples.
doi:10.1371/journal.pone.0038779.g002
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posted under Supporting Information.
Further validating the consistency of the expression data within
the identified functional categories, we observed co-regulation of a
number of functionally related genes (Figure 3).
Real time PCR. We performed a technical validation of our
microarray experiment and verified by real time PCR some of the
gene expression changes identified by microarray analysis (C1S,
C3, PFR1, SFRP1, CIDEA, ADIPOQ). All of the analyzed genes
showed expression changes consistent with those estimated by
gene chip analysis (Figure 4). The reported data have been
obtained using GAPDH as endogenous control gene, although
similar results have been obtained with HPRT1 (not shown).
Validation. To further validate at the biological level the
consistency of obtained results we prospectively performed two
additional biopsies, one in a FSHD T2-STIR + and one in a
FSHD T2-STIR – muscle and generated expression profiles for
these two muscle specimens. We normalized the two new arrays
together with the overall set of FSHD arrays previously generated
and performed a correlation analysis. As can be observed in
Figure 5, the two validation samples also clustered according to
their MRI pattern.
Expression of DUX4, DUX4-targets and 4q35 FSHD
candidate genes. Based on the signal level of the two probesets
interrogating DUX4 present in the HumanHT-12v4 BeadChip, we
observed no evidence of increased expression of this gene in our
FSHD samples. We checked for disregulations in the expression
levels of genes recently implicated in the DUX4-dependent
transcriptional network [26]. By directly browsing the expression
dataset, we observed overexpression of a number of DUX4-target
genes in two out of four FSHD T2-STIR + samples (ZSCAN4,
PRAMEF1, PRAMEF 4–6, PRAMEF9, MBD3L2, DEFB103B)
(Figure S4).
Other genes previously suggested to play a role in FSHD
pathogenesis like PITX1 [27] as well as D4Z4 proximal genes
(FRG1, FRG2, ANT1, LRP2BP) were expressed at comparable
levels in T2-STIR + and T2-STIR – FSHD muscles (not shown).
Discussion
Histopathological differences that emerge from the comparison
of FSHD T2-STIR + with T2-STIR – muscles include myopathic
alterations, increased endomysial spaces, presence of adipocytes in
perimysial areas and scattered necrotic phenomena. All our T2-
STIR + FSHD samples displayed inflammatory changes on
immunohistochemistry [21]. These alterations could represent the
beginning of a dystrophic process. At the molecular level, T2-
STIR + FSHD muscle is different from T2-STIR – FSHD muscle.
The differences described were consistent across different muscle
types. We ruled out a major effect of two possible confounders,
muscle type and genetic make up of the individual patients,
because quadriceps muscle samples were positioned in two
separate clusters according to their MRI pattern, as were the
two muscles taken from the same individual. Of note, the majority
of differentially expressed genes was upregulated in T2-STIR +
FSHD muscles, suggesting that the transition from T2-STIR – to
T2-STIR + is an ‘‘active’’ process. In T2-STIR + muscles we
found a significant upregulation of genes involved in innate and
Table 2. Functional categories and genes modulated in T2-STIR + FSHD with respect to IM.





Angiogenesis Angiogenin ANG 2,3725 0,0041
Angiopoietin-like 2 ANGPTL2 2,5002 0,0014
CD44 molecule CD44 2,4375 0,0035
CD34 molecule CD34 2,2935 0,0047
CD47 molecule CD47 1,6579 0,0013
Filamin B beta FLNB 2,2672 0,0056
Von Willebrand factor VWF 1,9606 0,0331
Slit homolog 3 SLIT3 2,6961 0,0047
Dedicator of cytokinesis 1 DOCK1 1,8760 0,0024
Secreted frizzled-related protein 1 SFRP1 4,8032 0,0026
Frizzled homolog 4 FZD4 2,1590 0,0051
Frizzled homolog 7 FZD7 1,3833 0,0401
Adipocyte presence, glycerolipid metabolism
and adipokine production
Cell death-inducing DFFA-like effector a CIDEA 9,7264 0,0009
Cell death-inducing DFFA-like effector c CIDEC 8,5623 0,0038
Perilipin 1 PLIN 5,6435 0,0017
Glycerol-3-phosphate acyltransferase GPAM 4,7128 0,0023
Alcohol dehydrogenase 1A ADH1A 4,1328 0,0016
Adiponectin, C1Q and collagen
domain containing
ADIPOQ 2,6172 0,0019
C1q and tumor necrosis factor
related protein 1
C1QTNF1 2,6181 0,0013
Leptin LEP 3,9142 0,0544
All of the cited genes were expressed to a higher extent in T2-STIR + FSHD muscles.
doi:10.1371/journal.pone.0038779.t002
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and alternative complement pathways. Extrahepatic synthesis of
complement factors by mesenchymal cells, such as endothelial cells
or adipocytes, or inflammatory cells, such as macrophages, has
been documented in inflammatory conditions [28]. Complement
activation could enhance chemoattraction of inflammatory cells
through the production of anaphilotoxins [29], or directly
modulate both T-cell and B-cell mediated adaptive immunity
[30]. Another innate immunity pathway induced in T2-STIR +
FSHD muscles is the Toll-like receptor (TLR) pathway [31]. TLR
Figure 3. Expression levels of single genes across samples. Co-regulation of functionally related genes: (A–F) members of complement
system, (G–H) co-regulated and selective induction in T2-STIR + FSHD muscles can be observed for SFRP1 and its receptor FZD4 and (I–L) for adipose
tissue genes and inflammatory adipokines.
doi:10.1371/journal.pone.0038779.g003
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endothelial cells, and also in PM and DM muscle fibers [32].
Moreover, we found evidence of upregulation of endothelial and
inflammatory cell adhesion molecules as well, likely contributing to
immune cell diapedesis.
Together with innate immunity, adaptive immunity processes
and in particular T-cell mediated immune responses were
induced. Accordingly, we have described increased presence of
activated circulating CD8+ T-cells in FSHD patients displaying
T2-STIR hyperintense muscles [21]. Of note, together with CD8+
T-cell surface and co-stimulatory molecules we found an increased
expression of genes involved in direct cell-mediated cytotoxicity,
such as granzyme-B and perforin. Another expression study
described a disregulation of chemokines from chromosome 4q in
FSHD patients [33]. Interestingly, in line with a recent report, half
of our T2-STIR + FSHD samples showed overexpression of
DEFB103B, which is a DUX4-dependent gene involved in the
modulation of both adaptive and innate immune responses, and
PRAME family cancer testis antigens [26]. This adds further
evidence to the fascinating perspective that bursts of DUX4
expression may induce damage by triggering a sustained
expression of genes causing a multifocal, inapposite immune
response [26].
T2-STIR + FSHD samples appear more similar to IM, and in
particular PM, while T2-STIR – muscles group with normal
controls. Although many transcriptional alterations were shared
between T2-STIR + FSHD and IM muscles, differences were
present that mainly regarded the overexpression in T2-STIR +
FSHD muscles of a number of proangiogenic factors and surface
proteins involved in cell-cell adhesion and cell-ECM interactions
(Table 2), consistently with previous findings [13]. To this regard,
an interesting group of genes is constituted by SFRP1, SFRP2,
FZD4 (which are co-regulated in our dataset) and FZD7. SFRP1
and 2 (secreted Frizzled-related proteins 1 and 2) are soluble
Figure 4. Real time PCR. Real time PCR analysis of selected gene expression. All the pathological samples display alterations consistent with the
gene chip expression level. Changes in transcript abundance are expressed as log2 ratio to control mean.
doi:10.1371/journal.pone.0038779.g004
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receptors, in the Wnt signaling pathway. Wnt/Frizzled signaling is
involved in normal angiogenesis and neovessel formation after
ischemic injury. In particular, SFRP1 acts through Frizzled 4 and
7 inducing vascular cell spreading [34] and proliferation [35] and
also on mesenchymal stem cells promoting neoangiogenesis [36].
Several T2-STIR + FSHD upregulated genes can be ascribed to
adipocyte metabolism. SFRP1 itself has proadipogenic activity
[37]. CIDEA and CIDEC (cell death inducing DFFA-like effector A
and C) encode proteins whose major localization is in white
adipose tissue and hepatocytes. However, minor contents of
CIDEA mRNA have been also detected in skeletal muscle [38] and
macrophages [39]. CIDEA has an inhibitory action on the lipolytic
process [40] and its expression in adipocytes is increased in human
cancer cachexia [41]. Other upregulated genes are involved in
glycerolipid metabolism (Table 2). Interestingly, in parallel with
adipocyte genes, we found a T2-STIR + FSHD selective
upregulation of genes encoding immunomodulatory adipokines
(Figure 3). ADIPOQ encodes adiponectin, a cytokine important for
macrophage recruitment that has been implicated in the
pathogenesis of rheumatoid arthritis [42]. Synthesis of adiponectin
by muscle cells under inflammatory conditions has been
documented as well [43]. C1QTNF1 encodes C1q and tumor
necrosis factor related protein-1, another cytokine associated with
a low-grade chronic inflammation status in adipose tissue [44]. We
could speculate that adipose tissue is not only a bystander of the
pathological process but may contribute to the maintenance of a
chronic inflammatory milieu. A large number of the alterations
described were not detectable in our T2-STIR – FSHD samples.
Therefore, the modulation of these pathways constitutes a specific
‘‘molecular signature’’ of the disease in this particular pathological
phase.
Conclusions
In FSHD, different muscles of each patient can, at the same
time, display different stages of the dystrophic process, character-
ized by peculiar and distinct histological and molecular alterations.
Thus, even though the aim of our study was not to identify what
distinguishes FSHD from normal muscle, it emerges that taking
one ‘‘snapshot’’ of the pathologic process could be not enough to
identify the process itself. This strict dependency on the timing and
the muscle in which the ‘‘snapshot’’ is taken could have
contributed to the diverse results obtained in different FSHD
gene expression studies [14,15,27,33]. This constitutes a substan-
tial difference from, for instance, Duchenne muscular dystrophy,
in which the molecular signature develops early and remains
constant all over the disease course [12].
The early stages of involvement of each FSHD muscle, defined
by the absence of T1-W hyperintensity, are identifiable through
muscle MRI based on their T2-STIR normal or hyperintense
signal. MRI with T2-STIR sequences, marking different phases of
the disease at the single muscle level, is a useful and reliable tool in
monitoring the progression of involvement of FSHD muscles and
with this aim it should be taken into consideration in the future
clinical trials in this disease.
The pronounced similarity with PM and DM of the T2-STIR +
FSHD muscle transcriptional profile, characterized by a marked
upregulation of genes involved in innate and adaptive immune
response, suggests that a selective and multifocal inflammatory
process may play an active role in the development of dystrophic
changes and consequently in disease advancement at single muscle
level. However, some aspects of our analysis may be limited in
power due to the moderate sample size. Further studies are needed
to clarify the exact significance of the specific biological processes
active in T2-STIR + muscles in determining muscle damage, in a
phase in which tissue modifications are still theoretically reversible.
Supporting Information
Figure S1 Early stages of involvement of FSHD muscles.
Images representative of T1-W normal/T2-STIR normal (T2-
STIR -, star) and T1-W normal/T2-STIR hyperintense (T2-STIR
+, arrowhead) muscles.
(TIF)
Figure S2 Hematoxylin-eosin stainings of T2-STIR + (A,
C) and T2-STIR – (B) FSHD muscles. Note the presence, also
evident at low magnification, of major myopathic changes, which
include increase in fiber size variability, central nuclei, inflamma-
tory infiltrates, increase in endomysial connective tissue in T2-
STIR + muscles. T2-STIR – muscle only displays mild myopathic
alterations. This differences are even more striking considering
that (B) and (C) are samples from the same patient. (A) sample 1;
(B) sample 12; (C) sample 2. Scale bar 100 mm.
(TIF)
Figure S3 Immunofluorescence of T2-STIR + FSHD
muscles with anti-CD8 (red, A) and anti-CD4 (red, B)
antibodies. CD8+ T-cells are the main component of endomy-
sial inflammatory infiltrates, while CD4+ T-cells predominate in
the perivascular regions. Muscle fibers are counterstained with
FITC-conjugated phalloidin (green), nuclei are stained with DAPI
(blue). (A) sample 3; (B) sample 5.
(TIF)
Figure S4 Expression levels of DUX4-target genes. Two
out of four T2-STIR + FSHD samples express the highest levels of
the DUX4-target genes ZSCAN4, PRAMEF1, PRAMEF 4–6,
PRAMEF9, MBD3L2 (A) and DEFB103B (B), which is also
induced in inflammatory myopathies.
(TIF)
Figure 5. Unsupervised hierarchical clustering of the validation
experiment.
doi:10.1371/journal.pone.0038779.g005
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